Literature DB >> 35739381

Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.

Yufu Peng1, Kefei Chen1, Bo Li1, Hongwei Xu1, Yonggang Wei2, Fei Liu3.   

Abstract

To date, there is little knowledge about the value of laparoscopic liver resection (LLR) for hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Thus, this study was performed to assess the perioperative and oncological outcomes of LLR for these patients by comparison with open liver resection (OLR). Between April 2015 and October 2018, a total of 217 resectable HCC patients with BCLC stage B were eligible for this study. Patients were divided into the LLR group and the OLR group according to different procedures. Propensity score matching (PSM) was conducted to adjust for known confounders. Short- and long-term outcomes were compared between the two groups. LLR was performed in 75 of the 217 included patients. After PSM, 72 patients with well-balanced baseline levels were enrolled into each group. Although the operative time was significantly longer in the LLR group than in the OLR group (median, 237.5 vs. 210 min, P = 0.024), the intraoperative blood loss was significantly less in the LLR group than in the OLR group (median, 200 vs. 350 ml, P = 0.005). Patients in the LLR group had fewer complications than those in the OLR group (P = 0.035). Furthermore, overall survival (OS, P = 0.827) and recurrence-free survival (RFS, P = 0.694) were comparable between the two groups. LLR for resectable HCC patients with BCLC stage B is safe and feasible in carefully selected patients and has superior perioperative outcomes and similar survival rates compared with OLR.
© 2022. Italian Society of Surgery (SIC).

Entities:  

Keywords:  BCLC stage B; Hepatocellular carcinoma; Laparoscopic hepatectomy; Open hepatectomy; Short-term outcomes; Survival rate

Mesh:

Year:  2022        PMID: 35739381     DOI: 10.1007/s13304-022-01309-2

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  26 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

2.  Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Authors:  H Kim; S W Ahn; S K Hong; K C Yoon; H-S Kim; Y R Choi; H W Lee; N-J Yi; K-W Lee; K-S Suh
Journal:  Br J Surg       Date:  2017-05-08       Impact factor: 6.939

3.  Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study.

Authors:  Alessandro Vitale; Patrizia Burra; Anna Chiara Frigo; Franco Trevisani; Fabio Farinati; Gaya Spolverato; Michael Volk; Edoardo G Giannini; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Mariella Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Antonio Gasbarrini; Rodolfo Sacco; Francesco Giuseppe Foschi; Gabriele Missale; Filomena Morisco; Gianluca Svegliati Baroni; Roberto Virdone; Umberto Cillo
Journal:  J Hepatol       Date:  2014-10-30       Impact factor: 25.083

4.  Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.

Authors:  R Ciria; P López-Cillero; A-B Gallardo; J Cabrera; M Pleguezuelo; M-D Ayllón; A Luque; L Zurera; J-J Espejo; M Rodríguez-Perálvarez; J-L Montero; M de la Mata; J Briceño
Journal:  Eur J Surg Oncol       Date:  2015-06-12       Impact factor: 4.424

5.  Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?

Authors:  Chin-Ta Lin; Kuo-Feng Hsu; Teng-Wei Chen; Jyh-Cherng Yu; De-Chuan Chan; Chih-Yung Yu; Tsai-Yuan Hsieh; Hsiu-Lung Fan; Shih-Ming Kuo; Kuo-Piao Chung; Chung-Bao Hsieh
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

7.  Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.

Authors:  Marco Sanduzzi-Zamparelli; Zoe Mariño; Sabela Lens; Victor Sapena; Gemma Iserte; Anna Pla; Núria Granel; Concepció Bartres; Neus Llarch; Ramón Vilana; Isabel Nuñez; Anna Darnell; Ernest Belmonte; Angeles García-Criado; Alba Díaz; Sergio Muñoz-Martinez; Carmen Ayuso; Luis Bianchi; Carla Fuster-Anglada; Jordi Rimola; Alejandro Forner; Ferran Torres; Jordi Bruix; Xavier Forns; Maria Reig
Journal:  J Hepatol       Date:  2021-11-29       Impact factor: 25.083

8.  Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT.

Authors:  Lei Yin; Hui Li; Ai-Jun Li; Wan Yee Lau; Ze-Ya Pan; Eric C H Lai; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Hepatol       Date:  2014-03-17       Impact factor: 25.083

9.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.

Authors:  Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S Orsini; Morris Sherman
Journal:  Liver Int       Date:  2015-03-25       Impact factor: 5.828

10.  Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Vogel; A Cervantes; I Chau; B Daniele; J M Llovet; T Meyer; J-C Nault; U Neumann; J Ricke; B Sangro; P Schirmacher; C Verslype; C J Zech; D Arnold; E Martinelli
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.